istock-172687351thedman

TheDman / iStockphoto.com

7 June 2018Americas

Astellas accuses Cipla of infringing overactive bladder patent

Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Astellas-backed Crescendo pairs up with Zai Lab in licensing deal

31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.

Cipla files defensive patent suit over Ofev generic

8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.

More on this story

Astellas-backed Crescendo pairs up with Zai Lab in licensing deal

31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.

Cipla files defensive patent suit over Ofev generic

8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.

More on this story

Astellas-backed Crescendo pairs up with Zai Lab in licensing deal

31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.

Cipla files defensive patent suit over Ofev generic

8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers